Development of lexatumumab in combination with temsirolimus against advanced renal cell carcinoma
Project/Area Number |
24592395
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Urology
|
Research Institution | Hyogo Medical University (2013-2014) Kagawa University (2012) |
Principal Investigator |
WU XIUXIAN 兵庫医科大学, 医学部, 講師 (10346645)
|
Co-Investigator(Kenkyū-buntansha) |
SUZUKI Toru 兵庫医科大学, 医学部, 講師 (00441296)
KANEMATSU Akihiro 兵庫医科大学, 医学部, 准教授 (90437202)
YAMAMO Shingo 兵庫医科大学, 医学部, 教授 (80322741)
杉元 幹史 香川大学, 医学部附属病院, 准教授 (10243768)
筧 善行 香川大学, 医学部, 教授 (20214273)
加藤 琢磨 香川大学, 医学部附属病院, 助手 (70625673)
|
Project Period (FY) |
2012-04-01 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2014)
|
Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
Keywords | lexatumumab / TRAIL-R2 / 腎癌細胞 / テムシロリムス / mapatumumab / TRAIL-R1 / apoptosis / Lexatumumab / 抗癌剤 / 腎癌培養細胞 / Mapatumumab / Lexatumumab / アポトーシス / アニソマイシン |
Outline of Final Research Achievements |
Development of anti-TRAIL receptor antibody in combination with temsirolimus against advanced renal cell carcinoma was performed. We found: (1) anti-TRAIL death receptor 2 antibody lexatumumab in combination with a new molecular targeted drug temsirolimus had an additive cytotoxic effect, although there was no a synergistic effect; (2) anti-TRAIL death receptor 1 antibody mapatumumab in combination with clinically achievable concentrations of epirubicin or pirarubicin had a synergistic cytotoxic effect; the synergistic effect was due to apoptosis via activation of the caspase cascades; (3) mapatumumab in combination with a protein inhibitor anisomycin had a synergistic cytotoxic effect.
|
Report
(4 results)
Research Products
(19 results)
-
[Journal Article] Synergistic induction of apoptosis by mapatumumab and anthracyclines in human bladder cancer cells2015
Author(s)
Ahmed SM, Wu X, Jin X, Zhang X, Togo Y, Suzuki T, Li Y, Kanematsu A, Nojima M, Yamamoto S, Sugimoto M, Kakehi Y.
-
Journal Title
Oncol Rep
Volume: 33
Issue: 2
Pages: 566-572
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs)2015
Author(s)
Aikawa K, Miyawaki T, Hitaka T, Imai YN, Hara T, Miyazaki J, Yamaoka M, Kusaka M, Kanzaki N, Tasaka A, Shiraishi M, Yamamoto S.
-
Journal Title
Bioorg Med Chem
Volume: 23
Issue: 10
Pages: 2568-2578
DOI
Related Report
Peer Reviewed / Open Access
-
-
[Journal Article] 転移性腎癌におけるスニチニブ2週投与1週休薬投与法の安全性と有効性2014
Author(s)
東郷容和, 嶋谷公宏, 花咲毅, 楊東益, 中西裕佳子, 長澤誠司, 橋本貴彦, 白石裕介, 田岡利宜也, 鈴木透, 呉秀賢, 樋口喜英, 兼松明弘, 野島道生, 土橋一成, 牧野雄樹, 清水洋祐, 金丸聰淳, 河野有香, 松敬優, 宇都宮紀明, 伊藤哲之, 川喜田睦司, 山本新吾
-
Journal Title
泌尿器科紀要
Volume: 60
Pages: 209-214
NAID
Related Report
Peer Reviewed / Open Access
-
-
-
[Journal Article] 維持期腎移植患者に対するエベロリムス投与の検討2013
Author(s)
野島道生, 白石祐介, 樋口喜英, 上田康生, 花咲毅, 中西祐子, 楊東益, 田岡利宜也,東郷容和,鈴木透,嶋谷公宏,呉秀賢, 長池紋子, 兼松明弘, 山本新語
-
Journal Title
日本臨床腎移植学会雑誌
Volume: 1
Pages: 180-185
Related Report
Peer Reviewed
-
-
[Journal Article] Expression of TRAIL, DR4, and DR5 in bladder cancer: correlation with response to adjuvant therapy and implications of prognosis2012
Author(s)
Li Y, Jin X, Li J, Jin X, Yu J, Sun X, Chu Y, Xu C, Li X, Wang X, Kakehi Y, Wu XX.
-
Journal Title
Related Report
Peer Reviewed
-
-
-
-
-
-
[Presentation] タクロリムス使用維持期症例におけるエロベリムス血中濃度の検討2014
Author(s)
樋口喜英, 野島道生, 嶋谷公宏, 花咲毅, 長澤誠司, 橋本貴彦, 東郷容和, 呉秀賢, 鈴木透, 長池紋子, 兼松明弘, 山本新吾
Organizer
第47回日本臨床腎移植学会
Place of Presentation
奈良
Related Report
-
-
-
-